heart failure with preserved ejection fraction


Also found in: Acronyms.

heart failure with preserved ejection fraction

Signs and symptoms of heart failure, including dyspnea, orthopnea or nocturnal dyspnea, and radiological evidence of pulmonary congestion, but an ejection fraction that exceeds 40%.
References in periodicals archive ?
Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2009;103:40510.
Formerly known as diastolic heart failure, the diagnosis now called heart failure with preserved ejection fraction is a condition in which the heart muscle becomes so stiff that its pumping chambers cannot properly fill with blood.
Yu et al., "A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?" Journal of Cellular and Molecular Medicine, vol.
Touyz et al., "Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fraction," International Journal of Vascular Medicine, vol.
The Hospitalization Burden and Post-Hospitalization mortality risk in heart failure with preserved ejection fraction: Results From the I-PRESERVE trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
Unmet needs in cardiovascular science and medicine: heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.
The combined company pipeline will include AeroVanc, an inhaled dry-powder vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in cystic fibrosis (CF) in preparation for a pivotal Phase 3 study, Molgradex, an inhaled nebulized GM-CSF to treat pulmonary alveolar proteinosis (PAP) currently in Phase 2/3 development and AIR001, an inhaled nebulised sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF) currently in Phase two development.
Lee et al., "Outcome of heart failure with preserved ejection fraction in a population-based study," The New England Journal of Medicine, vol.
Researchers at the University of Arizona have discovered that metformin, a drug commonly used to treat type 2 diabetes, might also be used to treat heart failure with preserved ejection fraction (HFpEF), a condition that is predicted to affect over 8 percent of people ages 65 or older by 2020.
European and North American heart failure management guidelines recommend sodium restriction for patients with systolic and diastolic heart failure with preserved ejection fraction. Available data now suggest that sodium restriction may actually increase mortality among patients with systolic heart failure.
Praliciguat is currently being studied in Phase II clinical trials in patients with diabetic nephropathy and in patients with heart failure with preserved ejection fraction, or HFpEF.
An important innovation in the guidelines is the new prominence afforded to heart failure with preserved ejection fraction, known as HFpEF (pronounced heff-peff).
Full browser ?